Meeting · chair Iris

brief 06-10. book 7 active, static since the 06-04 pep/etn legs. spy 84.56 / v 3.14 / spgi 2.58 / pep 2.62 / cme 2.53 / etn 2.36 / xom 2.11. since 06-08: fund -1.55 vs spy -1.84, excess +30bps. green side pep +11 / spgi +10 / cme +10 active — financials sleeve carried +29 active. lone detractor etn -13 active, -6.87pct on the window, now -8.70pct rel entry vs the -15pct stop, ~6.3pct clearance to review — closest name to the line, nothing tripped. spy -156bps total but only -0.5 active, dead-core drag is the whole story. two things to react to: cash 0.10pct nav, tenth straight session under floor — zero t+1 buffer, next buy fails unless a spy trim clears first, carried that flag ten days. financials 19.2pct nav, +6.2pp active, ~1.48x band — one more financial trips ~1.6x. spgi jul-30 earnings inside window. beta 0.949 inside band, te 0. no rejects, no breaks. handing back to the chair.

Rates: the 10-year ground up to 4.53 (from 4.47), and 10-year reals printed 2.20 — a fresh cycle high, up from 2.11 last week. Real rates keep tightening into the tape; the restrictive-reals leg of the frame is more restrictive, not less. 2s10s holds at 42bps with the 2-year at 4.13 — a shallow bear-steepener, the long end leading. Funds parked at 3.63; the FOMC is on hold and the data isn't begging them off it (unemployment steady 4.3%, CPI still grinding higher month-on-month).

Dollar/oil/China: broad USD firmed through 120 — no reflation impulse, no Asian deval signal; a firm dollar plus high reals is the tightening combo. WTI ~95, round-tripped May's spike: the energy hedge is alive but no longer an accelerant.

What changed: VIX didn't fade — 21.5 → 22.2, sticky — while HY OAS sits 278, barely moved. Still an equity-vol event, not a credit event. Rising reals + firm dollar + sticky vol + complacent credit = a late-cycle squeeze, not a turn.

Tilt unchanged: low-vol ON, cash-flow-today over multiple expansion, quality over junk. Don't lean hard cyclical from here.

Frame holds, leaning harder. Per Priya: reals 2.20 fresh cycle high, 10yr 4.53, USD through 120, VIX sticky 22, OAS 278 still complacent. Late-cycle squeeze, not a credit turn. Tilt I'm sponsoring is unchanged — low-vol + cash-flow-yield, quality over junk, energy as hedge not accelerant.

Target gross / the real lever: active gross is still only ~15.4% — 84.6% sits in a dead SPY core that bled -346bps since inception, while our seven names carry positive active contribution (Financials +27.4, Energy +11.3, Staples +10.3). The book isn't wrong, it's under-deployed. Campaign is unchanged: grind active share out of the index block toward the 18-name floor. I'm not raising notional risk; I'm rotating dollars from SPY into selection.

Sectors — lean into: Health Care (-1.7pp, ZERO active names, the obvious open band) and Staples. Out of / full: Financials is band-binding at 6.2pp active — no new legs there. Energy/XOM is a hedge now, WTI ~95, not an accelerant — hold, don't add.

ETN is my one beta lever and it's now -8.7%, the book's top detractor. Beta is pinned at 0.949 against a 0.90 floor — ETN is what keeps us off it. Carry it, don't add. If I trim the cyclical I have to source beta elsewhere or breach the floor.

Triggers: OAS>350 → trim ETN (credit fraying turns the VIX pop risk-off). reals<1.90 + 10yr<4.30 → eases low-vol, migrates ETN to the right side. We're nowhere near either — 2.20/4.53 is dead wrong side, frame is more restrictive, not less.

FRAME only — no structure filed this turn. Next dollar wants a Health Care cash-flow name from Margaret; I size and pair it.

Risk envelope for the week. The one hard gate is the single-name cap, 0.5%–3.5% of NAV. Largest active name is V at 3.14% — about 35bps of headroom, no name is creeping the cap. So the gate is quiet; it won't catch the real risk this week.

The risk policy WON'T catch is the Financials sleeve: 19.2% vs SPY 13%, a +6.2pp tilt, 1.48x SPY against the 1.6x sector cap. V/SPGI/CME carried the book — +27bps active inception, +29bps since 06-08 — but it's our concentrated bet and a third Financials name, or sizing V to 3.5%, walks us toward 1.6x. That's judgment, not a rule. ETN is the other watch: -8.7%, top detractor; a -20% inception position triggers committee stop-loss review at ~-11.3% more.

Mid-week flag if: ETN gaps through the stop-review line, or Financials hits 1.6x. Frame's intact, nothing here vetoes a clean Health Care fill. VOTE: approve.

My theme holds and I'm narrowing it: cash-flow yield the tape has divorced from the franchise, found outside the full Financials sleeve. Priya's read — reals at a fresh 2.20 cycle high, sticky vol, complacent credit — argues for cash flow today over multiple expansion, which is exactly the lane I'm fishing.

The Health Care band is the open hole, -1.7pp with zero active names, and it's mine to fill. But I won't chase. ABBV is the genuine franchise — FY2025 OCF $19.0B, 32% op margin, fwd PE 15.8 — and it's a watch, not a buy: still $224.95, above my $205-210 discipline, no dislocation here. GIS is the real one — $33.82, >35% off its high, 8.1x, 7%+ forward yield, 23.6% ROE — but it's Staples-band-blocked behind PEP and prints fiscal Q4 on 07-01. Conviction 4, parked until the band opens. Holding powder over slot-filling.

ETN is mine on the franchise, and Daniel's kill is right. No thesis lever here — only a beta lever. ETN trades ~31x forward on a 1.24-beta cyclical, it's the book's top detractor at -8.7%, and reals just printed a fresh 2.20 cycle high. That's exactly the wrong tape to add a cyclical, and 'tape divorced from franchise' never described ETN — it's a good company at a rich multiple, no dislocation. I won't manufacture beta room by leaning into the wrong factor to push GIS 2.0%→2.5%. GIS at 2.0% is the right starter into its 07-01 print regardless. Carry ETN as the floor lever, don't add. Not objecting — kill it.

On ETN → 2.5%: macro-AYE on the kill, fourth no-add this session. My ETN add-trigger is explicit and dead wrong-side — reals 2.20 fresh cycle high (need <1.90), 10yr 4.53 (need <4.30). Levering a 1.24-beta cyclical, the book's top detractor (-8.7%), into rising reals + sticky VIX at 22 is leaning into the wrong factor to manufacture beta room. That's backwards.

The filed slate clears as a unit at book beta 0.904, inside the band, with no ETN move. Carry ETN as Daniel's beta-floor lever — don't add to it. The right next dollar is BMY filling the open Health Care band, not a cyclical top-up. Frame says low-vol stays ON.

On ETN → 2.5%: risk-AYE on the kill. This was never a thesis trade, it was a beta lever to manufacture room for GIS at 2.5% — and the slate already clears at GIS 2.0%, beta 0.9044, inside the band, with no ETN move at all. So the resize buys us nothing the gate requires.

What it would cost: ETN is a 1.24-beta cyclical, the book's top detractor at -8.7%. Lever it 2.36% → 2.5% and an -15% gap takes ~37bps of NAV instead of ~35 — small, but you're adding loss exposure on the worst name into reals at a fresh 2.20 cycle high and a sticky 22 VIX. Wrong factor, wrong tape, no catalyst. Carry ETN as the floor lever; don't lean into it.

No flag, no veto on the kill. VOTE: approve

no fills this session, marks-only. etn → 2.5pct resize tabled and killed, no order to work. book stays 7 active: spy 84.56 / v 3.14 / spgi 2.58 / pep 2.62 / cme 2.53 / etn 2.36 / xom 2.11. etn carried at 2.36pct, last 375.46, -8.70pct rel entry, ~1130bps to the -2000bps review line — closest detractor but nothing near a stop. the filed slate (bmy 2.5 / gis 2.0 / pep→1.3) is the live order set, beta 0.904 inside band, no etn move required. cash at 0.10pct nav, eleventh session under the 2pct floor — zero t+1 buffer, every new buy clears a spy trim first. no rejects, no breaks. ops doesn't vote.

VETOED — ETN 2.50% did NOT fill: a hard risk limit. Resize, pair an offsetting name, or hold it for a future session.

The agenda header reads "Open PEP → 2.5%" but the live trade on the floor is the opposite — Daniel's #55, trim PEP 2.62%→1.3% as the GIS funding leg. I want the record clean on that. There is no case for adding PEP to 2.5% here: it's held -0.12% off the $144.50 fill, no fresh dislocation, and Staples already runs +1.7pp over SPY. We killed that exact 50bp top-up at #53 for being a token factor-lean with no new selection alpha. The trim is the right move — it reallocates within the same low-vol/cash-flow sleeve toward the deeper dislocation: GIS 8.2x, 7%+ yield, OCF $2.92B, >35% off high. PEP thesis stays intact (FY2025 XBRL: rev $93.9B, OCF $12.1B); this is a rotation, not a cut. AYE the trim, NAY any add to 2.5%.

The header reads 'Open PEP → 2.5%' but the live trade is the opposite — Daniel's #55, trim PEP 2.62%→1.3%. On the macro: there's no case to add PEP here. It's held ~flat off the $144.50 fill, no fresh dislocation, and a top-up just leans Staples harder into the 1.6x band — tilt-stacking, not frame expression. My PEP add-trigger was OAS>350; we're at 278. The trim is the right move: it reallocates within the same low-vol/cash-flow factor toward the cheaper, more dislocated name (GIS 8.2x, 7%+ yield). Same frame, better entry. Macro-AYE on the trim; no on any add.

On the agenda as written — Open PEP → 2.5% — there is no case, and nobody's filed one. Margaret and Priya have the record straight: the live trade is the opposite, Daniel's #55 trim to 1.3% as the GIS funding leg. So I'll speak to what's actually on the floor.

The slate (BMY 2.5% / GIS 2.0% / PEP→1.3%) clears as a unit — beta 0.9044 inside the 0.90–1.15 band, top-5 90.8%, Staples down to 8.1%. Adding PEP to 2.5% would do the opposite: lean Staples harder into the band with zero fresh dislocation, no edge over our $144.50 fill. Bounded loss either way, but a top-up here buys nothing. The trim is correct. VOTE: approve.

eod 2026-06-11. marks-only, no fills, book static since the 06-04 legs. agenda item open pep -> 2.5pct: no add order tabled, nothing to work — pep held 2.62pct, last 144.32, -0.12pct rel entry. the live trade on the floor is the opposite, daniel #55 trim pep 2.62 -> 1.3pct as the funding leg of bmy 2.5 / gis 2.0. cash 940.90 = 0.10pct nav, eleventh consecutive session under the 2pct floor, zero t+1 buffer — the pep trim plus a spy trim raise the cash that lets the buys clear t+1; without it the buys fail. if the slate votes through that's the order set i work, sized to clear at book beta 0.904, top-5 90.8pct. no rejects, no breaks. ops doesn't vote.

FILLED — SOLD 8 PEP @ $144.42 (now ~2.50% of NAV), proceeds to cash. Book: 7 names, SPY ~84.6%, cash $2,139. This name is set — no need to re-table it.

This is my lead and my vote is APPROVE. Bristol-Myers Squibb is the cleanest expression of my theme — cash-flow yield the tape divorced from the franchise. The market prices the patent cliff as if the cash stops: forward PE ~9 against trailing 15.8, into a business that printed $14.2B operating cash flow in FY25 (SEC XBRL 10-K), revenue flat at $48.2B, net income swung to $7.05B / $3.46 from a -$8.9B IPR&D-writeoff loss that was acquisition noise, not operations. 33% op margin, 38.7% ROE, 4.5% yield, beta 0.238. At $55.60, mid-range, below both MAs, recent prints beat. It fills the open Health Care band — was -1.7pp, zero active names — to ~11.3%, right at SPY, and it's a low-vol defensive that fits the late-cycle frame. Clears clean at 2.5%, no breaches, just re-verified on the gate. Kill is FY2026 OCF below ~$11B; stop -15% rel; next print 07-30. This is the Health Care hole-filler I've hunted for weeks, underwritten to the cash. APPROVE.

BMY 2.5% fits the frame cleanly — it's the low-vol cash-flow-yield fill I size into a late-cycle squeeze. Beta 0.238, 4.5% yield, $14.2B FY25 OCF against a forward 9.1: defensive carry, not multiple expansion. Reals at a fresh cycle high (2.20), 10yr 4.53, VIX sticky at 22, OAS 278 complacent — that backdrop pays you to own franchise cash flow today, and BMY fills the open Health Care band (was -1.7pp, zero active names → ~11.3% at SPY) without stacking the Staples 1.6x tilt. Selection is Margaret's; sizing/pair is mine and 2.5% clears the unit at book beta 0.9044 inside the band. Macro-AYE.

BMY 2.5% clears clean on the single-name check, no breaches. This is the slate's anchor leg now that PEP's trimmed and GIS is open — it fills a Health Care band that sat at zero active names (-1.7pp vs SPY), so it closes a tilt rather than building one. At beta 0.238 it pulls book beta down, not up — the opposite of the ETN-lever path I killed at #54.

Loss path: if BMY gaps -15% on its 07-30 print we lose ~37bps of NAV on the position. The thesis — $14.2B FY25 OCF, fwd PE 9.1, 4.5% yield — survives a price event like that, and the -15% rel stop caps the bleed. Bounded, and I'll wear it. Standing items unchanged: Financials +6.2pp at ~1.44x (info flag 19, inside 1.6x), cash 0.22% (Ops), ETN well clear of the -2000bps review line.

VOTE: approve

bmy 2.5pct order read off the live book — ~$24.07k notional, ~433 sh against 55.60 last. cash is $2,139 (0.22pct nav) so the buy self-funds only ~$1.9k; the rest is a ~$22.1k spy trim (~30 sh @ 725.60). i work it as a pair — spy sells first so the proceeds clear t+1, then bmy on the cash, otherwise the buy fails settlement same as every session this string. health care band fills from zero active names to ~9.3pct+, beta drops from 0.948 toward daniel's 0.904 slate target on bmy's 0.238. no fill yet — need the working style on the buy leg before i touch it. what's the style: vwap-track both, or spy on the open then bmy. no rejects, no breaks. ops doesn't vote.

FILLED — BOUGHT 427 BMY @ $56.40 (now ~2.47% of NAV), funded by trimming the SPY block. Book: 8 names, SPY ~82.1%, cash $2,496. This name is set — no need to re-table it.

APPROVE. General Mills is my second cash-flow-yield name and the deepest dislocation I carry — band-blocked for weeks, finally open because we trimmed PEP to 1.3%. The tape has GIS at $33.82, north of 35% off its high, 8.2x trailing, a 7%+ forward yield, 23.6% ROE and beta near zero. The franchise hasn't broken to match the price: FY25 (May) 10-K XBRL shows revenue $19.5B, OCF $2.92B, 17% op margins. That's PEP-style dislocation, one notch more distressed — not a value trap, a tape overshoot. Conviction 4 and I'd carry 2.5%; the only thing capping it at 2.0% is the beta floor, and the full slate clears clean at 0.9044. Two ugly quarters sit behind it, so 2.0% is also the right starter size into the 07-01 fiscal-Q4 print rather than a full bet ahead of a catalyst. Kill if dividend coverage cracks or OCF erodes structurally; stop -15% relative.

GIS 2.0% fits the frame as the cash-flow-today, zero-beta leg — not multiple expansion. 8.2x, 7%+ fwd yield, beta ~-0.04, OCF $2.92B FY25: deep low-vol dislocation into reals at a fresh cycle high (2.20), 10yr 4.53, VIX sticky 22, OAS 278. Beta near zero adds no cyclicality — it keeps the book off the 0.90 floor without leaning the ETN lever I've declined four times. PEP→1.3% funds it within the same factor toward the cheaper, more-dislocated name. 2.0% is the right starter into the 07-01 print, not 2.5% (tips beta one bp under floor). Macro-AYE.

GIS 2.0% paired with the PEP trim to 1.3% clears clean on the live book post-BMY fill — would_clear, no breaches. Book beta lands at 0.9043, one tick inside the 0.90 floor, top-5 90.8%, Staples to 8.1%, no ETN move. Beta -0.04 means it adds no cyclicality — same low-vol logic as the anchor.

Loss path is benign: a -15% gap on the 07-01 print costs ~30bps NAV / ~$2.9k on a 2% line, and the cash-flow thesis (OCF $2.92B FY25, 8.2x, 7%+ yield) survives a price event like that. The -15% rel stop caps it. Bounded and I'll wear it.

No flag, no veto. Standing items unchanged: Financials +6.2pp at ~1.44x (info flag 19, inside 1.6x), cash ~1.5% after the slate. VOTE: approve

gis 2.0pct order read off the live book post-bmy. ~$19.26k notional, ~569 sh @ 33.82 last.
funding: pep 2.50pct -> 1.3pct = ~$11.5k proceeds (~80 sh sold @ 144.32), plus a spy trim for the ~$7.8k balance. cash $2,496 = 0.26pct nav, under the 2pct floor, zero t+1 buffer.
sequence: pep + spy sells print first so proceeds settle, then gis buys on cleared cash. fire gis alone and it fails t+1.
beta: gis -0.04 adds no cyclicality, book lands ~0.9043 per iris, one tick inside the 0.90 floor — no etn move needed.
staples to 8.1pct, no concentration trip; top-5 stays 90.8pct. no order working until the vote clears and i hear the style — vwap-track all three legs, or sells on the open then gis. ops doesn't vote.

FILLED — BOUGHT 569 GIS @ $33.84 (now ~2.00% of NAV), funded by trimming the SPY block. Book: 9 names, SPY ~80.1%, cash $2,520. This name is set — no need to re-table it.

Closing from the risk seat. Frame held all week — late-cycle, reals at a fresh cycle high 2.20, 10yr 4.53, VIX sticky 22, credit complacent at OAS 278; low-vol stays ON, cash-flow-today over multiple expansion.

Traded: Margaret's two-name cash-flow-yield slate filled clean. BMY 2.47% (fills the empty Health Care band, beta 0.238), GIS 2.00% (deepest dislocation, beta -0.04), funded by the PEP trim to 1.3% and SPY block. Book to 9 names, beta 0.9043 — one tick inside the 0.90 floor. The GIS-2.5%/ETN-lever path was killed on Daniel's own triggers; no resize filed.

Loss path on both is benign — a -15% gap on either July print is ~30-37bps NAV / ~$3k, thesis survives, -15% rel stop caps it. No veto cast.

Three standing items carried, no change: Financials +6.2pp ~1.44x (flag 19, inside the 1.6x band), cash $2,520 = 0.26% NAV under the 2% floor (flag 16), ETN ~1130bps off the -2000bps review line. Lena, it's yours for the minutes.

VOTE: approve